27 Apr 2018

A view from the marketing side MS drugs...for anyone who had doubts


How to Profit from Human Suffering 101! 

We of course knew this was going on, but it's incredible to see it in black and white like this.  I also checked out the migraine article - that's one of my issues. 

Finch - Western PA USA

ME/CFS since 1991 - CPn diagnosed June 07 - began Cipro 760 mg 2x per day - added NAC 600 mg 2x per day July 07 - Stopped Cipro and began Doxy 100mg 1x per day on 9/18/07

ME/CFS since 1991. Cpn diagnosed 6/07. CAP started 7/07. NAC 2400mg per day, doxycycline 100mg 2x per day, azithromyicin 250mg M-W-F. 8/09 switched from Flagyl to Tindamax 500mg 2x per day for 5-day pulse.

It's a cold economic reality that there's more money to be made by treating sick people than by curing them.  A cure is a one-time (or short term) deal while treatment guarantees you a lifetime annuity.   

CAP for M.S. since 8/2007. Currently: 200 mg Dox. Waiting to start Zith & Flagyl.

CAP for M.S. 8/2007 - 3/2009.  Twentieth pulse metronidazole + INH completed 3/12/2009.  Intermittent treatment thereafter until 11/20/2009.  

There was a rather depressing article in the Wall Street Journal, about a year ago, saying that the drug industry had decided that antibiotics and antivirals were unprofitable to develop, because people only take them for a week or ten days, and those sorts of sales can't pay back the cost of developing a drug and getting it approved for sale, today.

If they only knew how long some of us take antibiotics!

Norman -

From personal professional experience, I can say that your post is very true. 

Drug companies are looking for "life style" drugs (such as Viagra, Rogaine or Botox) for which people will self pay and not require drug formulary approval AND/OR for the novel high end products in markets with "unmet" needs such as Crohn's, Scleroderma, MS or Lupus, etc...

When  a drug company has one of these types of products in a disease state with "unmet" needs, they will be able to charge as much as they generally like - hence the price of the injectable CRABS AND automatically go on drug formularies. 

Often drugs that are pursued for one of these "unmet" need areas work really well in other disease states - for instance - a Lupus drug might also work really well in asthma.  But the drug company won't fund the research for a disease state (like asthma) in which the drug shows clear evidence of safety and effectiveness because it would cost the drug company $200m plus to pursue that indication and then they would have the hassle of drug formularies and only being "allowed" by insurance for the most refractory of patients.    The ROI would be poor. 

Again, antibiotics are out because duration of therapy is too short, antivirals - particularily retrovirals are out because you are expected to give more away to 3rd world countries  than you sell and you have big press/activist issues and so - to solve these problems - most drug companies quietly shut down research in these areas and instead focused nearly solely on "lifestyle" drugs and areas of "unmet" needs for which they can charge the farm.

In truth - a large part of what a drug company will research is based on how/if they think they can get on an insurance companies formulary because the issue of generics is off the table.  Major disease states now have very little if any research due to all of these issues including asthma, infections, high blood pressure, reflux, etc..

I will throw this in for the heck of it - many drug companies have known for a very long time about the connection between autoimmune diseases and antibiotics - particularily mycoplasma and CPN.  They did proof of concept studies and evaluated the market Vs the cost of research and ROI - I think you know what happened.

Daisy-Caregiver- Balo's Concentric Sclerosis. Began CAP 5/10/07. Doxy 200 mg, Mino 100 BID 9/1/07, AZI 250mg QD 9/10/07, NAC 1800 mg, HD Flagyl Pulses, Novantrone, Prednisone & daily lb of supplements.

Daisy - Husband on CAP 5/07.  Husband died from Acute Myelogenous Leukemia Secondary to the Infusion of Novantrone.  Ie - the treatment with the conventional MS drugs killed him. Daisy on her own CAP 11/2012. 

With all due respect to the editors of the Wall Street Journal, I disagree.  New drugs that are only taken for a short time can be developed profitably.  Those profits will not, however, be sufficient to provide double-digit growth in earnings year after year that the pharmaceutical industry (and investors in pharmaceutical stocks) have come to expect. 

CAP for M.S. since 8/2007. Currently: 200 mg Dox. Waiting to start Zith & Flagyl.

CAP for M.S. 8/2007 - 3/2009.  Twentieth pulse metronidazole + INH completed 3/12/2009.  Intermittent treatment thereafter until 11/20/2009.  

sadly, money & lots of it drives the pharmaceutical industry; not healing.

CFIDS/ME 25yrs, FMS, IBS, EBV, Cpn, (insomnia - melatonin, GABA, tarazadone, temazepam, novocyclopine, allergy formula, 2 gm tryptophan), Natural HRT peri-M, NAC 2.5 gm, 6-07 Doxy 200 mg day pm, Azith 375 mg M/W/Fday, 9-30-07 2nd pulse 1 X 250 mg Metro

CFIDS/ME, FMS, MCS, IBS, EBV, CMV, Cpn, H1, chronic insomnia, Chronic Lyme, HME, Babesia, Natural HRT-menopause, NAC 2.4 gm,Full CAP 6-2-07, all supplements+Iodorol, Inositol-depression, ultra Chitosan, L lysine Pulse#27 04-19-10 1gm Flagyl/day-5 days<

A figure thrown around a lot in the pharmaceutical industry is that developing a new drug costs $800 million, on average. Of course the researchers who actually invent the drug don't cost nearly that much; the bulk of those costs are the costs of running clinical trials to satisfy the FDA.

That figure includes the costs of all the failed trials that one goes through, on the way to finally getting a drug approved. So if you're really, really good -- better than the researchers at the average drug company -- you can expect to develop a drug for less. But the costs are still way above what all but a very few rich people can afford, so most everybody who wants to develop a drug has to look for financing of some sort. And financiers, in general, aren't qualified to judge who is really, really good at developing drugs; so the figure they use when deciding whether or not to loan money is the industry average. And, yes, they do want a double-digit return on investment (not necessarily double-digit earnings growth, although that's one way of doing it), to compensate them for the large inherent risk of the business. Otherwise they'll take their money to more profitable and/or less risky areas of the economy. None of this is an absolute barrier to developing new antibiotics; but it's far from being an encouraging environment.

Of course, at present, we don't seem to particularly need new antibiotics for treating Cpn. We're not even using Ketek, a new antibiotic which is highly active against Cpn. So drug research doesn't have much of a constructive role to play.